Chicago, Illinois
Cancer surgery and procedure trials in Chicago, IL
90 cancer surgery and procedure studies are recruiting participants at sites in Chicago as of November 18, 2026, according to ClinicalTrials.gov. Cancer Surgery Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Chicago at a glance
- 90 studies are recruiting at a site in Chicago.
- By phase: Early Phase 1 (2), Phase 1 (4), Phase 1/2 (6), Phase 2 (30), Phase 2/3 (2), Phase 3 (31), Phase 4 (1), No phase (8), Observational (6). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (56), government (31), industry (3).
- By research area: Lymphoma (23), Lung Cancer (22), Prostate Cancer (17), Breast Cancer (14), Pancreatic Cancer (8), Melanoma (6).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Chicago
Basic details from each study's public record (the 30 most recently updated of 90). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
- Registry record
- NCT05564377 · updated
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- Phase 2
- Ages 35 and older
- Female participants
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05941520 · updated
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern Medicine Cancer Center Old Irving Park · Northwestern University
- Registry record
- NCT07391774 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · Mount Sinai Hospital Medical Center · Northwestern University
- Registry record
- NCT06058377 · updated
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Observational
- Ages 40 to 75
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
- Registry record
- NCT05334069 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Lung cancer studies recruiting in Chicago
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04665739 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT06498635 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- John H Stroger Jr Hospital of Cook County
- Registry record
- NCT07388524 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT06287775 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · Rush MD Anderson Cancer Center · University of Illinois
- Registry record
- NCT06096844 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Illinois
- Registry record
- NCT04181060 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Prostate cancer studies recruiting in Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Rush MD Anderson Cancer Center · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT03866382 · updated
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05691465 · updated
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Northwestern University · Rush MD Anderson Cancer Center · University of Illinois
- Registry record
- NCT04423211 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Melanoma studies recruiting in Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Illinois
- Registry record
- NCT05136196 · updated
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Northwestern University · Swedish Covenant Hospital
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Lymphoma studies recruiting in Chicago
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT03739814 · updated
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT05272384 · updated
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Swedish Covenant Hospital · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT06337318 · updated
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study sites
- Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04726241 · updated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Alliance for Clinical Trials in Oncology
- Registry record
- NCT07724457 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Northwestern University · University of Chicago Comprehensive Cancer Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Advocate Illinois Masonic Medical Center · Lurie Children's Hospital-Chicago · Mount Sinai Hospital Medical Center
- Registry record
- NCT05675410 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT06649812 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Chicago
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04858334 · updated
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05372614 · updated
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Northwestern University · University of Illinois
- Registry record
- NCT06807437 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Ask about studies near Chicago
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Illinois
All Illinois locations
109 studies recruiting across 74 cities.
Peoria
44 studies recruiting.
Decatur
42 studies recruiting.
Effingham
41 studies recruiting.
Springfield
41 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a surgery or another procedure, as each study is coded in the registry.
Cancer Surgery Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections